Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years

HYPOTHESIS: Breast cancer has become the most common cancer in Korean women in recent years, with continuously increased incidence rates attributed to westernized lifestyles. DESIGN: Retrospective case series evaluating the changing patterns of clinical characteristics in breast cancer during the last 15 years. SETTING: Hospitalized patients with breast cancer in a university medical center. PATIENTS: A total of 5001 breast cancer patients who underwent surgery between July 1989 and March 2004 at the Asan Medical Center. MAIN OUTCOME MEASURE: Clinicopathologic data were collected using the online Korea Breast Cancer Registration Program, including factors such as age, symptoms, stage, surgery, reconstruction, risk factors, and survival. RESULTS: The median age of patients slightly increased from 44 years in 1991 to 46 years in 2003. The most frequent age group was the fifth decade (41.7%) and premenopausal women younger than 50 years (64.9%). The proportion of asymptomatic patients detected by screening mammography increased from 3.8% in 1991 to 21.0% in 2003 (P<.001). The proportion of early breast cancer (stages 0 and I) increased from 34.2% in 1991 to 48.8% in 2003 (P=.013). Breast-conserving surgery has increased continuously from 5.1% in 1991 to 39.1% in 2003 (P<.001). Twelve percent of all patients who underwent mastectomies had immediate reconstruction, and the proportion showed an increasing trend, especially in skin-sparing mastectomy and transverse rectus abdominis myocutaneous flap reconstruction. Five-year observed survival rates were 84.1%. Five-year survival rates according to stages were as follows: (1) 98.5%, stage 0; (2) 95.3%, stage I; (3) 86.0%, stage II; (4) 65.0%, stage III; and (5) 29.3%, stage IV. The number of patients with specific risk factors, such as early menarche and late first delivery, significantly increased. Of 263 high-risk patients examined for the BRCA mutation, mutations were found in 20 patients (7.6%), with 13 cases with BRCA1 and 7 cases with BRCA2. CONCLUSIONS: The present study showed a continuous increase in the number of patients with breast cancer; the proportion of young patients, asymptomatic patients, early breast cancer, breast-conserving surgery, and immediate reconstruction after mastectomy; and the number of patients with risk factors. These results suggest that the clinical characteristics of Korean breast cancer patients reflect the patterns of Western countries.     

Refining esophageal cancer staging

OBJECTIVE: Cancer staging is dynamic, reflecting accrual of knowledge and experience in treatment. The objectives of this study were to assess current esophageal cancer staging and to determine whether refinements of classification and stage grouping are necessary. METHODS: From 1983 through November 2000, 480 patients underwent esophagectomy without induction therapy. Depth of tumor invasion (T), regional lymph node status (N), distant status (M), number of metastatic regional lymph nodes, and histopathologic type and grade were subjected to survival-tree analysis, multivariable Cox and hazard function analysis, and residual misclassification risk analysis. RESULTS: Inhomogenity of survival was found within and lack of distinction was found between current American Joint Committee on Cancer staging groups, supporting the need for refinement. T1 and N1 were redefined on the basis of survival differences. T1a is intramucosal cancer, T1b is submucosal cancer (P =.008), N1 is 1 or 2 metastatic regional lymph nodes, and N2 is 3 or more metastatic regional lymph nodes (P =.01). Current subclassification of M1 is not warranted (P =.9). Histopathologic type (P =.17) and grade (P =.3) minimally refined staging. Reassignment of staging groups constrained by American Joint Committee on Cancer definitions of stages 0 and IV produced less monotonic, distinctive, and homogeneous survival than free assignment of staging groups. CONCLUSIONS: Current American Joint Committee on Cancer staging of esophageal cancer is inadequate. Refinement requires redefinition of T1, N1, and M1 classifications. Stage grouping within the constraints of American Joint Committee on Cancer definitions produces less accurate prognosis than free assignment based on survival data.     

Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial

Background Neoadjuvant chemotherapy can increase the rate of breast-conserving surgery in patients with operable breast cancer. However, uncertainty remains regarding surgical procedures and predictors for successful breast-conserving surgery.Methods This study was an analysis of surgical data of a representative data subset of 607 patients enrolled in the GEPARDUO study. This prospective, multicenter, phase III study randomly assigned patients with operable breast cancer (≥ 2 cm) to neoadjuvant 8-week dose-dense doxorubicin plus docetaxel or a 24-week schedule of doxorubicin plus cyclophosphamide followed by docetaxel (AC-DOC).Results Breast conservation was attempted in 493 (81.2%) patients, but 43 patients eventually required mastectomy, thus resulting in a breast-conserving surgery rate of 74.1%. Breast-conserving re-excision was performed in 61 patients (12.4%). Factors associated with a significantly higher breast-conserving surgery rate were a prechemotherapy tumor size ≤ 40 mm, nonlobular histological characteristics, treatment with AC-DOC, clinical response, postchemotherapy tumor size ≤ 20 mm, and treatment in a larger center (>10 enrolled patients). Nonlobular histological characteristics and intraoperative frozen-section analysis for margin evaluation were associated with significantly lower reoperation rates (P = .015).Conclusions Breast conservation after neoadjuvant chemotherapy is feasible in most patients with operable breast cancer. For surgical planning, tumor characteristics and response to neoadjuvant chemotherapy should be taken into account. Improved breast-imaging modalities are necessary to improve detection of residual disease after neoadjuvant chemotherapy, especially when breast cancer is of lobular invasive histology. Margin assessment by intraoperative frozen-section analysis is helpful to avoid reoperation. To achieve an optimal result, an interdisciplinary surgical approach is important.     

Trends in surgical treatment of younger patients with breast cancer in Australia and New Zealand

Background: The optimal surgical treatment of early breast cancer in young women is not fully determined, while past reports indicate a trend to the increased use of breast‐conserving surgery (BCS). This study aims to assess the trend in Australia and New Zealand of BCS use between 1999 and 2006 and to determine pathological factors associated with it. Methods: Data on cancer characteristics and surgical procedures in younger patients with early breast cancer reported to the National Breast Cancer Audit have been analysed. Results: There was little change in the rate of BCS over the last 7 years with an overall rate of 53%. The main factors associated with the use of BCS are low histological grade, absence of extensive intraductal carcinoma (EIC), negative lymph node involvement, unifocal tumour and small tumour size. Conclusion: Between 1999 and 2006, the use of BCS for early breast cancer treatment in younger women was stable. These results show that surgeons contributing data to the National Breast Cancer Audit appear to use pathological factors that are known to increase the risk of local recurrence after BCS, in selecting mastectomy for younger women.     

An analysis of breast cancer in hungary: Experience of the national institute of oncology,Budapest

Breast cancer is the most common type of cancer in women throughout the world (18%), with a yearly morbidity that is already over half a million. Its incidence in Hungary is increasing in each age group, and the mortality is strikingly high. This study was conducted to assess the effectiveness of breast-conserving surgery in comparison to more radical surgery on a large group of patients. During the 15 years between 1980 and 1994, a total of 6,358 patients with primary breast cancer underwent surgery at the National Institute of Oncology in Budapest, Hungary, as breast-conserving surgery in 2,026 patients (31.8%). Breast-conserving surgery is being performed in an ever-increasing number of patients, followed by adjuvant radiochemotherapy in premenopausal patients, or radiohormone therapy in menopausal patients. During follow-up, recurrence was found in only 5.9% of the patients who underwent breast-conserving treatment. Thus, according to our experience, breast conservation therapy for the management of breast cancer offers favorable results, provided that the preconditions to this treatment are adequately met.     

95例乳腺癌保乳治疗近期观察

目的探讨乳腺癌保乳治疗的方法与疗效。方法95例Ⅰ-Ⅱ期原发性乳腺癌,施行局部扩大切除并腋窝淋巴结清扫,手术后患侧乳房接受放射治疗。结果手术后6个月随访,患者本人对保留乳房的满意率100％,十分满意者为92％。经随访2～51个月,平均随访17个月,仅1例同侧乳腺局部复发,2年局部复发率1．4％。无远处转移和死亡病例。结论Ⅰ-Ⅱ期乳腺癌实施保乳治疗,近期疗效满意,远期效果有待长期随访观察。     

Prospects for standardization of surgical treatment for breast cancer

Surgical treatment of breast cancer in general guided cancer surgery in the direction of extensive radical operations until two decades ago. More recently, the trend has been toward conservative, less-extensive surgery. Moreover, breast cancer has become a model case for establishing standardization of surgical care of cancer. The Japanese Breast Cancer Society issued "Guidelines for Breast-Conserving Therapy" in 1999, and the Clinical Research Group for Establishing Guidelines for Standardized Diagnosis and Treatment for Breast Cancer became active in 2002 under the auspices of the Ministry of Health, Welfare and Labor. There are several areas of controversy in terms of surgical care in breast cancer. Examples are yet-immature breast-conserving surgery which is performed with wide variations (15-90%) depending upon the institution, and sentinel lymph node biopsy which must await long-term results before being recognized as standard care. The installation of expensive diagnostic devices indispensable for standardized surgical care might not be necessary at each institution, and it must be noted that postoperative follow-up policies practiced in Japan differ greatly from those recommended by the American Society of Clinical Oncology. Despite the anticipated difficulties, a consensus on what constitutes standardized surgical treatment for breast cancer might be easily reached among breast cancer surgeons. However, it may be somewhat difficult to popularize the standardized surgical treatment among ordinary general surgeons in Japan, since there is a wide disparity in the level of clinical care offered by individual physicians and healthcare institutions. Standardization of medical care guided by the government is mainly designed to reduce healthcare costs, which is instrumental in eliminating unnecessary medical interventions and may in turn shed light on valuable medical care advances. This may be the moment for the Japanese Surgical Society and its members who practice life-saving surgery to lead a genuine national medical reformation.     

Serum levels of transforming growth factor beta1 in patients with breast cancer

HYPOTHESIS: Transforming growth factor beta1 (TGF-beta1) may be related to breast cancer progression. DESIGN: Prospective study. SETTING: University hospital. PATIENTS: Sixty consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated. The control group consisted of 14 patients with benign breast tumors (7 with fibrocystic disease and 7 with fibroadenoma). INTERVENTION: Venous blood samples were collected before the surgery. Sera were obtained by centrifugation and stored at -70 degrees C until assayed. Serum concentrations of TGF-beta1 were measured by quantitative sandwich enzyme immunoassay. Data on primary tumor stage, age, estrogen receptor status, lymph node status, distant metastases, and TNM staging (according to the Union Internationale Contre le Cancer) were reviewed and recorded. MAIN OUTCOME MEASURES: Measurements of preoperative serum TGF-beta1 levels in patients with breast cancer. RESULTS: The mean +/- SD value of serum TGF-beta1 in patients with invasive breast cancer was 498.7 +/- 249.7 pg/mL and in the control group was 495.2 +/- 225.5 pg/mL (P =.96). However, there were significantly higher serum levels of TGF-beta1 in patients with more advanced lymph node status (P =.04), more advanced TNM stage (P =.005), and poorer histological grade (P =.02). In multivariate analysis, TNM staging (P =.02) was demonstrated to be the independent factor related to significantly higher serum levels of TGF-beta1. CONCLUSIONS: Patients with more advanced TNM stages were shown to have higher serum TGF-beta1 levels. Thus, serum TGF-beta1 levels may reflect the severity of invasive breast cancer.     

New challenges in the treatment of early breast cancer or surgery for early breast cancer ... can less be more?

Breast cancer is a major public health problem of great interest and importance to physicians in a variety of specialities. The incidence of the disease has increased dramatically, heightening concern among physicians and women in general. In addition, long-term results are now available from clinical trials initiated in the 1970s and 1980s to evaluate the usefulness of early detection with mammography and physical examination, breast-conserving treatment with limited breast surgery and irradiation, and adjuvant systemic therapy with hormonal therapy and chemotherapy. Furthermore, in the light of newly gained knowledge, new strategies for addressing this problems have been proposed. In this review, we will summarize the evidence evaluating the strategies for diagnosis and therapy initiated in the 1970s and 1980s, and will describe the prospects for prevention and for more specific treatments bases on evolving biologic knowledge. Our review will only focus on early breast cancer, discussing the following topics: Breast Cancer screening: Who should be screened and how often?; New technologies in Breast Cancer Diagnosis; Selection of patients for Breast-conserving therapy; Management of the axilla in primary breast cancer or "Is sentinel lymph node biopsy useful?"; Expanded use of adjuvant systemic therapy; Genetic predisposition for Breast Cancer; Clinical options for Women at high-risk for Breast Cancer.     

Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group

OBJECTIVE: To confirm evidence that breast-conserving treatment (BCT) does not impair the prognosis in breast cancer patients as compared to mastectomy and to argue that it be regarded as the treatment of choice in stage I and II disease. SUMMARY BACKGROUND DATA: Scientifically, survival rates in breast cancer have been shown to be stage-dependent, but independent of the extent of surgical breast tissue removal, as long as the resection margins are free of tumor infiltration. METHODS: Between 1984 and 1997, six different trials conducted by the Austrian Breast & Colorectal Cancer Study Group accrued a total of 4,259 women with hormone-responsive disease. The authors selected and compared three patient groups (n = 3,316) according to pathologic stage, age, and the surgical procedure applied. RESULTS: Over this interval, the BCT rate in the premenopausal node-positive subgroup experienced a highly significant increase from 27.2% to 73.2% overall. In the group of postmenopausal node-negative patients, the BCT rate grew significantly by 37.3% to 77.3% in total. With an overall BCT rate growing from 22.5% to 56.8% in postmenopausal node-positive women, those presenting with T1 tumors saw a significant increase from 35.1% to 65.9%. Mortality and local recurrence rates proved stable or even decreased considerably over time and in all subgroups. CONCLUSIONS: The presented outcome of BCT rates, significantly improved over this 16-year period and in no way counterbalanced by higher local recurrence or death rates, reflects an excellent example of surgical quality control. BCT can safely be regarded as the standard of therapy for T1 and increasingly for T2 disease. Especially in multi-institutional adjuvant breast cancer trials, the highest priority should be given to breast-conserving procedures.     

Predictors of breast asymmetry after breast-conserving operation for breast cancer

BACKGROUND: Although breast-conserving surgery is the standard of care for early-stage breast cancer, many women report breast asymmetry after this procedure. Risk factors for poor esthetic outcomes are not well understood. STUDY DESIGN: A self-administered survey was sent to patients who underwent lumpectomy (n = 898) at the University of Michigan Medical Center between January 2002 and May 2006 (n = 714, response rate = 79.5%). Breast asymmetry was assessed using items from the Breast Cancer Treatment and Outcomes Survey. Responses were summed to generate a score, and linear regression was used to generate adjusted breast asymmetry scores by patient-related factors (age, body mass index [BMI], tumor size, and tumor position in the breast) and treatment factors (reexcision lumpectomy, radiation therapy, and postoperative seroma). RESULTS: Patient-related risk factors for breast asymmetry included younger age (asymmetry score: 18.7 versus 16.2, p = 0.03), higher BMI (17.1 versus 19.2, p = 0.007), and larger tumors (16.7 versus 19.1, p = 0.01). Resection of superior medial tumors and inferior lateral tumors was also associated with substantially higher asymmetry. Treatment-related risk factors for asymmetry included reexcision lumpectomy (18.1 versus 16.9, p = 0.013), postoperative seroma (19.3 versus 17.2, p = 0.005), and radiation therapy (17.9 versus 15.0, p = 0.008). Increasing breast asymmetry score was associated with a higher odds of desiring breast reconstruction (odds ratio = 1.2, 95% CI, 1.13 to 1.30). CONCLUSIONS: Both patient- and treatment-related factors place women at risk for poor esthetic outcomes after breast-conserving surgery. Oncoplastic and reconstructive options should be considered for those at a higher risk for poor esthetic outcomes at the time of consultation.     

������-�ش󼡸��ϼ��꼴���鷿�����о�

??Immediate breast reconstruction with partial latissimus dorsi and pectoralis major compound muscular flap ZHANG Bin*, FENG Rui, GE Jie, et al. Department of Breast Cancer, Cancer Hospital of Tianjin Medical University, Tianjin 300060, China. Corresponding author: CAO Xu-chen, E-mail: CXC@medmail.com.cn Abstract Objective To investigate immediate breast reconstruction following skin-sparing mastectomy in breast carcinoma patients by using thoracodorsal artery descending branche based partial latissimus dorsi and pectoralis major compound muscular flap with breast prothesis. Methods Breast reconstruction were performed in 16 patients with operation procedures described above, and the traits and indications of the procedure were analyzed. The patients were admitted between January 2006 and March 2009 at Cancer Hospital of Tianjin Medical University and Tianjin Central Hospital for Gynaecology and Obstetrics. Results Fifteen patients (16 breasts) underwent the breast reconstruction procedure following immediate mastectomy as described above. Three patients had experienced seroma, which was treated and cured by aspiration method. Forteen patients performed chemotherapy after being confirmed as invasive breast cancer by pathology and none of them had experienced relative complications. The median follow up time was 16 months (2??36 months), reconstructive breast demonstrated of good shape, soft texture, and without any capsular contracture. Conclusion Breast reconstruction with partial latissimus dorsi-pectoralis major compound muscular flap and breast prothesis is a simple and safe procedure, which reserved the functionof latissimus dorsi and pectoralis major and conserved the donor site. The procedures is suitable for the patients who were either inappropriate for or unable to comply with breast-conserving surgery and radiotherapy is not required in pre- and intra-operation evaluation.     

早期乳腺癌病人保乳手术标本病理切缘评价临床价值研究

目的 探讨早期乳腺癌保乳手术标本病理切缘评价的临床价值。方法 回顾性分析2013-01-01-2017-12-31北京大学第一医院乳腺疾病中心接受保乳手术的早期乳腺癌病人资料,探讨病理切缘范围与预后的关系,以及术中冰冻病理与术后石蜡病理对于保乳手术切缘评价的一致性。结果 共474例保乳病例纳入研究,总体复发转移发生率为3.4%,局部复发率（LRR）1.5%,5年无病存活率（DFS）95.7%,5年总存活率（OS）96.8%。术后石蜡与术中冰冻病理学检查对于保乳切缘评价的符合率为100%,首次切缘阳性与阴性相比,局部复发率差异无统计学意义（χ2=1.371,P=0.242）。切缘阴性病人不同切缘宽度的无病存活率和总存活率差异均无统计学意义（χ2=0.123,P=0.726;χ2=0.077,P=0.781）,局部复发率差异也无统计学意义（χ2=1.808,P=0.613）。结论 术中冰冻与术后石蜡病理学检查评价保乳手术切缘符合率高,不同宽度阴性切缘病人的无病存活率和局部复发率差异无统计学意义。     

早期乳腺癌保乳手术与改良根治术的临床疗效及生活质量比较

目的:比较保乳手术与改良根治术治疗早期乳腺癌的临床效果及生活质量。方法:回顾性分析2004年4月—2007年4月经保乳手术治疗的95例(保乳组)早期乳腺癌患者临床资料,并与同期行改良根治术95例(改良组)早期乳腺癌患者进行对比。结果:保乳组与改良组的局部复发率、转移率、生存率间无统计学差异(P>0.05);保乳组和改良组乳房外观美学效果"优良"率分别为93.7%和0(P<0.05);保乳组术后5年存活患者生活质量评分亦明显高于改良组(83.66±3.70 vs.73.07±4.85)(P<0.05)。结论:对于早期乳腺癌,保乳手术在获得与改良根治术相同疗效的同时,能明显改善患者术后的生活质量;掌握好保乳手术适应证、规范的手术切除和术后个体化综合治疗是手术成功的关健。     

保乳手术治疗高龄乳腺癌患者的临床分析

目的:探讨保乳手术治疗早期高龄乳腺癌患者的临床效果。方法:筛选114例早期高龄(≥60岁)乳腺癌患者,随机分为乳腺癌局部扩大泛切除术组,即保乳手术组(57例)和传统乳腺癌根治术组(57例),分析比较两组的围手术期观察指标和临床疗效。结果:保乳手术围手术期的出血量和总引流量少,引流管拔除时间短,与传统手术组相比,差异有统计学意义(P<0.05);保乳手术组美容效果优良率为94.74%,远高于传统手术组(3.51%);保乳手术组与传统手术组在局部复发率、远处转移率和生存率等方面无统计学差异(P>0.05)。结论:保乳手术联合术后辅助治疗,对老年乳腺癌患者机体损伤小、恢复快,可满足患者的美学要求,因此,保乳手术联合术后辅助治疗的方案可在早期老年乳腺癌患者中推广。     

胚系BRCA突变年轻乳腺癌术式选择对预后影响的Meta分析

背景与目的 携带胚系BReast CAncer基因（gBRCA）突变的年轻乳腺癌患者同时具有年轻与基因突变带来的双重风险。目前对于gBRCA突变早期乳腺癌患者是否可行保乳治疗目前尚无一致结论。本研究通过Meta分析探讨不同手术方式对gBRCA突变的年轻乳腺癌患者预后的影响，以及该影响是否有人种差异。方法 检索多个国外数据库，收集比较gBRCA突变早期乳腺癌患者行保乳手术与全乳切除术预后差异的临床研究，对无复发生存（RFS）、无转移生存（MFS）、乳腺癌特异性生存（BCSS）、总生存（OS）等指标进行Meta分析。结果 最终纳入6篇研究（中国2篇，欧美4篇），共2 140例gBRCA突变患者，中位年龄38~47岁。Meta分析结果显示，总体人群中，gBRCA突变患者行保乳手术较全乳切除术复发风险增高（RFS：HR=1.91，95% CI=1.03~3.54，P<0.05），但两种术式的MFS、BCSS、OS差异均无统计学意义（均P>0.05）；中国人群中，gBRCA突变患者行保乳手术较全乳切除术复发风险增高（RFS：HR=1.63，95% CI=1.10~2.41，P<0.05），两种术式的其余指标差异均无统计学意义（均P>0.05），欧美人群中，两种术式的上述指标差异均无统计学意义（均P>0.05）。结论 对于欧美人群，保乳手术不是gBRCA突变早期年轻乳腺癌术后预后的风险因素；但在中国人群中，gBRCA突变早期年轻乳腺癌患者行保乳手术可能具有更高的复发风险，需在术式选择的医疗决策时充分告知。     

Telomerase Activity Levels for Evaluating the Surgical Margin in Breast-Conserving Surgery

To evaluate the efficiency of measuring telomerase activity levels in clinical diagnosis, we performed a semiquantitative analysis of telomerase activity in breast tumors and compared the results with the histological findings. Breast tissue adjacent to areas of cancer were also serially resected and checked for telomerase activity. The amount of telomerase activity in the breast cancers ranged widely, from 0.36 to 1 180 units/μg, with 31 of the 34 (91.2%) showing a value above 1.0 unit/μg. None of the normal breast tissues including mastopathy, and only 4 (23.5%) of 17 benign breast masses had values above 1.0 unit/μg. Telomerase activity was detectable in serial sections of adjacent tissues as far as 10 mm from the macroscopic tumor margin with histologically detectable cancer cells. Furthermore, telomerase activity was detectable in the scrape specimens obtained from the stump of the surgical margins for breast-conserving surgery, and this activity was in accordance with the histological findings. These findings show that conducting a semiquantitative assay of telomerase activity is useful for evaluating the surgical margin in breast-conserving surgery. Received: May 10, 2000 / Accepted: September 26, 2000     

A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery

BACKGROUND: There are a variety of surgical choices for women with early-stage breast cancer, including breast-conserving surgery, mastectomy, or mastectomy plus reconstructive surgery. This report examines some of the factors that affect these choices and the costs of the various treatment options. METHODS: Data from the Virginia Cancer Registry were linked to insurance claims from the Trigon Blue Cross and Blue Shield Company for women with local and regional staged breast cancer from 1989 to 1991 in Virginia. Multivariate analyses and cost studies were performed. RESULTS: There were 592 women who underwent breast-conserving surgery (BCS, 26%), mastectomy (58%), or mastectomy plus reconstruction (16%). Increasing age reduced the use of reconstruction. The choice of reconstruction was not affected by tumor size, nodal status, or race. Sixty percent of women had immediate breast reconstruction at the time of mastectomy; the majority had the implant procedure. The cost of BCS ($21,582) was higher than that of mastectomy ($16,122, P < .01). The costs for BCS and mastectomy were significantly lower than for mastectomy plus reconstruction ($31,047, P < .05). The 2-year cost for immediate reconstruction was $8200 less than for delayed procedures and was similar to the cost of BCS. CONCLUSIONS: Age was the driving force in reconstruction decisions. Clinical factors such as tumor size and nodal status were more important for the choice between BCS and mastectomy. There are significant cost differences between the various procedures. For a similar cosmetic outcome, BCS is less expensive than breast reconstruction. When reconstruction is required, a simultaneous procedure is less expensive.     

新辅助化疗及保乳手术在Ⅱ|Ⅲ期乳腺癌中的治疗作用

目的探讨新辅助化疗及保乳手术在Ⅱ,Ⅲ期乳腺癌治疗中的作用。方法对观察组46例Ⅱ,Ⅲ期乳腺癌经新辅助化疗后接受保乳手术治疗的患者进行随访观察,并与59例患者对照研究。新辅助化疗方案为表阿霉素60 mg/m2第1天静脉注射,紫杉醇150 mg/m2。第2天持续3 h静脉滴注,21 d为1个疗程。保乳手术方式为象限切除或肿块局部广泛切除联合腋窝淋巴结清除。对照组常规行根治性切除术。术后对乳房外形及局部复发、远处转移进行随访观察。结果新辅助化疗后,观察组术前肿瘤病灶临床完全缓解(CR)9例,部分缓解(PR)37例。术后病理学检查发现,观察组癌细胞均有不同程度的变性、坏死,细胞间质水肿,纤维增生,炎性细胞浸润;其中病理完全缓解(PCR)4例。对保乳综合治疗(放疗+化疗)结束后1年的31例患者进行外形评估,其中优19.4%(6/31),良58.1%(18/31),差22.6%(7/31)。观察组局部复发率为8.7%(4/46),对照组为6.8%(4/59),两组比较无统计学意义(P0.05);观察组远处转移率为6.5%(3/46),与对照组(15.3%,9/59)比较无统计学意义(P0.05)。结论新辅助化疗后行保乳手术治疗Ⅱ,Ⅲ期乳腺癌基本是安全的,可达到根治性手术的效果。新辅助化疗,规范化切除,术后放疗、化疗是保乳治疗成功的关键。